Primary Sclerosing Cholangitis (PSC)

Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

Apr 22, 2019

Potential Impact of cfDNA Technologies in Disease Management

By Ethan McConkey, Moderator, @ethanmcconkey

2019-05-07 DA

Cell free DNA (cfDNA) are degraded DNA fragments released to the blood stream during health and disease. This discovery was made more than 50 years ago. However, it was not until recently with the advent, scalability and affordability of next generation sequencing that cfDNA has become an approach to study biomarkers for disease progression. In our recent review on cfDNA, published in the "Therapeutic Advances in Gastroenterology", we discuss the principals, current advances and future applications about cfDNA technologies including their use in gastrointestinal and liver disease

The PDF of the published article can be found here.

Join others discussing PSC

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.

Please login or register to send an invite.